The positive data presented by Gritstone Bio on its COVID-19 vaccine at a prestigious global conference could increase investor confidence in the company's research and development capabilities, potentially leading to increased interest in its stock. The emphasis on durability and broad utility suggests the vaccine could have significant market potential, which might translate into future revenue growth for the company.